156 related articles for article (PubMed ID: 32471565)
41. Role of KEAP1/NRF2 and TP53 Mutations in Lung Squamous Cell Carcinoma Development and Radiation Resistance.
Jeong Y; Hoang NT; Lovejoy A; Stehr H; Newman AM; Gentles AJ; Kong W; Truong D; Martin S; Chaudhuri A; Heiser D; Zhou L; Say C; Carter JN; Hiniker SM; Loo BW; West RB; Beachy P; Alizadeh AA; Diehn M
Cancer Discov; 2017 Jan; 7(1):86-101. PubMed ID: 27663899
[TBL] [Abstract][Full Text] [Related]
42. Glutamine antagonist DRP-104 suppresses tumor growth and enhances response to checkpoint blockade in
Pillai R; LeBoeuf SE; Hao Y; New C; Blum JLE; Rashidfarrokhi A; Huang SM; Bahamon C; Wu WL; Karadal-Ferrena B; Herrera A; Ivanova E; Cross M; Bossowski JP; Ding H; Hayashi M; Rajalingam S; Karakousi T; Sayin VI; Khanna KM; Wong KK; Wild R; Tsirigos A; Poirier JT; Rudin CM; Davidson SM; Koralov SB; Papagiannakopoulos T
Sci Adv; 2024 Mar; 10(13):eadm9859. PubMed ID: 38536921
[TBL] [Abstract][Full Text] [Related]
43. Modification of platinum sensitivity by KEAP1/NRF2 signals in non-small cell lung cancer.
Tian Y; Wu K; Liu Q; Han N; Zhang L; Chu Q; Chen Y
J Hematol Oncol; 2016 Sep; 9(1):83. PubMed ID: 27601007
[TBL] [Abstract][Full Text] [Related]
44. Precision Immunotherapy for STK11/KEAP1-Mutant NSCLC.
Ricciuti B; Garassino MC
J Thorac Oncol; 2024 Jun; 19(6):877-882. PubMed ID: 38849167
[No Abstract] [Full Text] [Related]
45. A clinical drug library screen identifies clobetasol propionate as an NRF2 inhibitor with potential therapeutic efficacy in KEAP1 mutant lung cancer.
Choi EJ; Jung BJ; Lee SH; Yoo HS; Shin EA; Ko HJ; Chang S; Kim SY; Jeon SM
Oncogene; 2017 Sep; 36(37):5285-5295. PubMed ID: 28504720
[TBL] [Abstract][Full Text] [Related]
46. RNA-binding motif protein 47 inhibits Nrf2 activity to suppress tumor growth in lung adenocarcinoma.
Sakurai T; Isogaya K; Sakai S; Morikawa M; Morishita Y; Ehata S; Miyazono K; Koinuma D
Oncogene; 2016 Sep; 35(38):5000-9. PubMed ID: 26923328
[TBL] [Abstract][Full Text] [Related]
47. Kelch-like ECH-associated Protein 1-dependent Nuclear Factor-E2-related Factor 2 Activation in Relation to Antioxidation Induced by Sevoflurane Preconditioning.
Cai M; Tong L; Dong B; Hou W; Shi L; Dong H
Anesthesiology; 2017 Mar; 126(3):507-521. PubMed ID: 28045693
[TBL] [Abstract][Full Text] [Related]
48. Effects of deficiency of Kelch-like ECH-associated protein 1 on skeletal organization: a mechanism for diminished nuclear factor of activated T cells cytoplasmic 1 during osteoclastogenesis.
Sakai E; Morita M; Ohuchi M; Kido MA; Fukuma Y; Nishishita K; Okamoto K; Itoh K; Yamamoto M; Tsukuba T
FASEB J; 2017 Sep; 31(9):4011-4022. PubMed ID: 28515152
[TBL] [Abstract][Full Text] [Related]
49. A Naturally-Occurring Dominant-Negative Inhibitor of Keap1 Competitively against Its Negative Regulation of Nrf2.
Qiu L; Wang M; Zhu Y; Xiang Y; Zhang Y
Int J Mol Sci; 2018 Jul; 19(8):. PubMed ID: 30042301
[TBL] [Abstract][Full Text] [Related]
50. In the Presence of KRAS Comutations With STK11 or KEAP1 Monoimmunotherapy Does Not Work, but Is Not Chemoimmunotherapy Also an Overtreatment?
Kus T; Aktas G
J Thorac Oncol; 2023 Aug; 18(8):e83-e84. PubMed ID: 37479333
[No Abstract] [Full Text] [Related]
51. Epigenetic versus Genetic Deregulation of the KEAP1/NRF2 Axis in Solid Tumors: Focus on Methylation and Noncoding RNAs.
Fabrizio FP; Sparaneo A; Trombetta D; Muscarella LA
Oxid Med Cell Longev; 2018; 2018():2492063. PubMed ID: 29643973
[TBL] [Abstract][Full Text] [Related]
52. Keap1-Nrf2 Interaction Suppresses Cell Motility in Lung Adenocarcinomas by Targeting the S100P Protein.
Chien MH; Lee WJ; Hsieh FK; Li CF; Cheng TY; Wang MY; Chen JS; Chow JM; Jan YH; Hsiao M; Hua KT; Kuo ML
Clin Cancer Res; 2015 Oct; 21(20):4719-32. PubMed ID: 26078391
[TBL] [Abstract][Full Text] [Related]
53.
Nabeshima T; Hamada S; Taguchi K; Tanaka Y; Matsumoto R; Yamamoto M; Masamune A
Am J Physiol Gastrointest Liver Physiol; 2020 Mar; 318(3):G419-G427. PubMed ID: 31961719
[TBL] [Abstract][Full Text] [Related]
54. Keap1 loss promotes Kras-driven lung cancer and results in dependence on glutaminolysis.
Romero R; Sayin VI; Davidson SM; Bauer MR; Singh SX; LeBoeuf SE; Karakousi TR; Ellis DC; Bhutkar A; Sánchez-Rivera FJ; Subbaraj L; Martinez B; Bronson RT; Prigge JR; Schmidt EE; Thomas CJ; Goparaju C; Davies A; Dolgalev I; Heguy A; Allaj V; Poirier JT; Moreira AL; Rudin CM; Pass HI; Vander Heiden MG; Jacks T; Papagiannakopoulos T
Nat Med; 2017 Nov; 23(11):1362-1368. PubMed ID: 28967920
[TBL] [Abstract][Full Text] [Related]
55. ERBB3 and IGF1R Signaling Are Required for Nrf2-Dependent Growth in KEAP1-Mutant Lung Cancer.
Vartanian S; Lee J; Klijn C; Gnad F; Bagniewska M; Schaefer G; Zhang D; Tan J; Watson SA; Liu L; Chen H; Liang Y; Watanabe C; Cuellar T; Kan D; Hartmaier RJ; Lau T; Costa MR; Martin SE; Merchant M; Haley B; Stokoe D
Cancer Res; 2019 Oct; 79(19):4828-4839. PubMed ID: 31416841
[TBL] [Abstract][Full Text] [Related]
56. CDK20 interacts with KEAP1 to activate NRF2 and promotes radiochemoresistance in lung cancer cells.
Wang Q; Ma J; Lu Y; Zhang S; Huang J; Chen J; Bei JX; Yang K; Wu G; Huang K; Chen J; Xu S
Oncogene; 2017 Sep; 36(37):5321-5330. PubMed ID: 28534518
[TBL] [Abstract][Full Text] [Related]
57. Simultaneous K-ras activation and Keap1 deletion cause atrophy of pancreatic parenchyma.
Hamada S; Shimosegawa T; Taguchi K; Nabeshima T; Yamamoto M; Masamune A
Am J Physiol Gastrointest Liver Physiol; 2018 Jan; 314(1):G65-G74. PubMed ID: 28971839
[TBL] [Abstract][Full Text] [Related]
58. Directly interact with Keap1 and LPS is involved in the anti-inflammatory mechanisms of (-)-epicatechin-3-gallate in LPS-induced macrophages and endotoxemia.
Chiou YS; Huang Q; Ho CT; Wang YJ; Pan MH
Free Radic Biol Med; 2016 May; 94():1-16. PubMed ID: 26878775
[TBL] [Abstract][Full Text] [Related]
59. Keap1/Nrf2 pathway in kidney cancer: frequent methylation of KEAP1 gene promoter in clear renal cell carcinoma.
Fabrizio FP; Costantini M; Copetti M; la Torre A; Sparaneo A; Fontana A; Poeta L; Gallucci M; Sentinelli S; Graziano P; Parente P; Pompeo V; De Salvo L; Simone G; Papalia R; Picardo F; Balsamo T; Flammia GP; Trombetta D; Pantalone A; Kok K; Paranita F; Muscarella LA; Fazio VM
Oncotarget; 2017 Feb; 8(7):11187-11198. PubMed ID: 28061437
[TBL] [Abstract][Full Text] [Related]
60. EPHA5 mutation was associated with adverse outcome of atezolizumab treatment in late-stage non-small cell lung cancers.
Li Z; Zhou Q; Wang Q; Wang H; Yue W
BMC Pulm Med; 2022 Sep; 22(1):356. PubMed ID: 36123678
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]